Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

Rapcabtagene autoleucel (YTB323) for patients with first line high-risk large B-cell lymphoma: Phase II interim results

Jason Westin, Julio Chavez, Stephen J. Schuster et al. Nov 03, 2025 pp. 670-670 10.1182/blood-2025-670

Abstract Introduction: Although ~70% of patients (pts) with large B-cell lymphoma (LBCL) respond to frontline (1L) chemoimmunotherapy, outco...

Optimizing time to IV methotrexate initiation for planned admissions to the inpatient hematology/oncology service

Sean Taasan, Savannah Brock, Monica Chintapenta et al. Nov 03, 2025 pp. 6187-6187 10.1182/blood-2025-6187

Abstract Background Parkland Hospital serves as a safety net for Dallas County and provides comprehensive cancer services. Efficient utiliza...

Founder effects and consanguinity shape beta-thalassemia genetics: A five-year hospital-based cohort study from Pakistan

Zeeshan Ahmed, Ayaz Khan, Haq Khan et al. Nov 03, 2025 pp. 2920-2920 10.1182/blood-2025-2920

Abstract Background: Pakistan represents one of the highest global β-thalassemia burdens, bearing an estimated carrier frequency of 5-7% and...

Identification of novel variants in congenital fibrinogen deficiency by next-generation sequencing

Kunyuan Kou, Long Chen, Yani Lin et al. Nov 03, 2025 pp. 3052-3052 10.1182/blood-2025-3052

Abstract Background: Congenital fibrinogen deficiency (CFD) is a rare inherited bleeding disorder characterized by reduced fibrinogen levels...

Multivariable-adjusted validation of IWG23-defined peripheral blood complete remission (PB-CR) and IWG23 response criteria in 2,042 patients with MDS, CMML or AML treated with diverse first-line therapies: Insights from the AML-001 trial (NCT01074047) and the ‘austrian myeloid registry’ (NCT04438889) of the AGMT study group

Lisa Pleyer, Xu Zhang, Manuel Drost et al. Nov 03, 2025 pp. 3859-3859 10.1182/blood-2025-3859

Abstract Introduction Morphologic complete remission (CR) or composite CR (cCR) requiring bone marrow evaluations (BMEs) remain the gold stan...

Allosteric inhibition of RAN decreases mir-126 biogenesis in endothelial cells and controls Acute Myeloid Leukemia growth

Melissa Valerio, Guido Marcucci, Le Xuan Truong Nguyen et al. Nov 03, 2025 pp. 3294-3294 10.1182/blood-2025-3294

Abstract RAS-related nuclear protein (RAN), a small GTPase of the RAS superfamily, cycles between active (GTP-bound) and inactive (GDP-bound...

Oligocentric castleman disease: Clinical characteristics and surgical outcomes from a single-centre retrospective study

Yukai Duan, Xudong Zhang, Mingzhi Zhang Nov 03, 2025 pp. 6572-6572 10.1182/blood-2025-6572

Abstract Oligocentric Castleman Disease (OCD) is a unique subtype of Castleman disease (CD). Some reports suggest that the clinical features...

KMT2A::AF6 fusion protein localizes to PML nuclear bodies and undergoes ATO-induced degradation: A potential novel therapeutic approach for KMT2A::AF6-rearranged Acute Myeloid Leukemia

Claudia Tregnago, Sara Perpinello, Ambra Da Ros et al. Nov 03, 2025 pp. 753-753 10.1182/blood-2025-753

Abstract Chromosomal rearrangements of the human KMT2A gene are key drivers of both pediatric and adult acute leukemias. Over 100 known in-f...

From theory to therapy: Predicting response to chemotherapy with multiomic longitudinal profiling of peripheral blood in AML

Jennifer Rangel Ambriz, Ziang Chen, Yu-Hsuan Fu et al. Nov 03, 2025 pp. 5284-5284 10.1182/blood-2025-5284

Abstract Acute myeloid leukemia (AML) is an aggressive hematological malignancy with 5-year survival rate of less than 32%, mainly due to tr...

In Vivo pan CAR therapy utilizing circular RNA for treatment of multiple myeloma

Rebecca Silver, Jeffrey Schindler, Oba Oseghali et al. Nov 03, 2025 pp. 4117-4117 10.1182/blood-2025-4117

Abstract Recently, traditional ex vivo-generated chimeric antigen receptor T (CAR-T) cell therapies have shown success in the clinic for onc...

Outcomes of adult T-cell acute lymphoblastic leukemia/lymphoma in a real-world cohort: A single institution experience in the deep south

Maris Hardee, Jay Jarodiya, Kimo Bachiashvili et al. Nov 03, 2025 pp. 8084-8084 10.1182/blood-2025-8084

Abstract Background: Acute lymphoblastic leukemia/lymphoma (ALL/LBL) is a rare, genomically heterogenous group of diseases with 20% of cases...

Luspatercept rescues the disease phenotype of a congenital dyserythropoietic anemia type II patient and an in vitro patient-derived iPSC erythroid differentiation model

Linxiu Mao, Yuan Xue, Xiaoyu Ran et al. Nov 03, 2025 pp. 3218-3218 10.1182/blood-2025-3218

Abstract There is currently no standardized treatment regimen established for Congenital dyserythropoietic anemia (CDA), supportive care and...

Real-world treatment patterns and outcomes of patients with myelodysplastic syndrome by line of therapy

Diego Adrianzen Herrera, Jacob Ambrose, Andrew Belli et al. Nov 03, 2025 pp. 601-601 10.1182/blood-2025-601

Abstract Introduction: Myelodysplastic syndrome (MDS) is a complex and heterogeneous malignancy characterized by bone marrow failure, cytope...

Asciminib in chronic myeloid leukemia: Superior efficacy and favorable safety outcomes from a systematic review and meta-analysis

Ahmet Sarici, Lokman H. Tanrıverdi, Adrian V. Hernandez et al. Nov 03, 2025 pp. 7298-7298 10.1182/blood-2025-7298

Abstract Abstract Introduction: Asciminib is a novel allosteric inhibitor targeting the myristoyl pocket of the BCR:ABL1 protein in patients...

Real-world (RW) use of fixed-duration (FD) ibrutinib+venetoclax (Ibr+Ven) in patients (pts) with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): Pooled analysis of REALITY-worldwide (WW) and REALITY-2 prospective cohort studies

Catherine Thieblemont, Emmanuelle Tchernonog, Talha Munir et al. Nov 03, 2025 pp. 3903-3903 10.1182/blood-2025-3903

Abstract Introduction FD Ibr+Ven is approved as first-line (1L) treatment (tx) for CLL/SLL in 78 countries across Asia, Europe, the Middle Ea...

Cell-free DNA is associated with central venous catheter-associated deep venous thrombosis in critically ill children

Hilary Whitworth, Hem Regmi, Anna Prykhodko et al. Nov 03, 2025 pp. 317-317 10.1182/blood-2025-317

Abstract Introduction: Neutrophil extracellular traps (NETs) are webs of histone-coated DNA released from activated neutrophils. Increased N...

Chronic myeloid leukaemia in the pregnancy: Experience at a university hospital in Paraguay

Ruth Lopez Cabrera, José Zarza, Rodrigo Santacruz et al. Nov 03, 2025 pp. 7299-7299 10.1182/blood-2025-7299

Abstract Introduction Chronic myeloid leukaemia (CML) is defined by the presence of the BCR::ABL1 oncogene, resulting from a translocation b...

Complement dysregulation during vaso-occlusive episodes can predict development of acute chest syndrome in pediatric patients with sickle cell disease

Akshaya Arjunan, Maya Maarouf, Adrianna Westbrook et al. Nov 03, 2025 pp. 1167-1167 10.1182/blood-2025-1167

Abstract Introduction Vaso-occlusive episodes (VOE) and acute chest syndrome (ACS) remain the leading cause of hospitalizations and morbidit...

BCMA CAR T-cell therapy in newly diagnosed transplant-ineligible multiple myeloma: An open label, single-arm, phase 2 study (CAREMM-001)

Wenqiang Yan, Chenxing Du, Hesong Zou et al. Nov 03, 2025 pp. 2293-2293 10.1182/blood-2025-2293

Abstract Background: BCMA-directed CAR-T cell therapies have demonstrated deep and durable responses in relapsed/refractory multiple myeloma...

Trends in first-author retention in ASH accepted works from 2019–2024

Taha Huda, Bret Miller, Cole Miller et al. Nov 03, 2025 pp. 8217-8217 10.1182/blood-2025-8217

Abstract Background: Continued engagement in hematology research is crucial for continued improvement of patient outcomes and is an importan...

Point-of-care ultrasound in outpatient hematology clinic: A quick approach to evaluating deep vein thrombosis, venous reflux, and their implications for post-thrombotic syndrome

Tro Sekayan, Terrence Sun, Annette von Drygalski Nov 03, 2025 pp. 742-742 10.1182/blood-2025-742

Abstract Background: Venous thromboembolism (VTE) is a prevalent condition frequently managed by hematologists. Lower extremity (LE) deep ve...

Recurrent splenic infarction in triple-positive antiphospholipid syndrome despite therapeutic anticoagulation

Marina Khan, Faisal Shariff, Ateeb Parvez et al. Nov 03, 2025 pp. 6655-6655 10.1182/blood-2025-6655

Abstract Introduction: Splenic infarction is an uncommon condition often linked to autoimmune or inflammatory diseases. Its causes are broad...

The ASH consa consortium on newborn screening in Africa for sickle cell disease: Interim updates of progress in screening, follow-up and supporting initiatives

Obiageli Nnodu, Bernard Awuonda, Lulu Chirande et al. Nov 03, 2025 pp. 944-944 10.1182/blood-2025-944

Abstract Introduction: Children born with sickle cell disease (SCD) in sub-Saharan Africa (SSA) are at >50% risk for under age 5 mort...

Correlation of T cell fitness of apheresis products with response to CAR T-cell therapy in patients with relapsed or refractory large B-cell lymphoma: A prospective observational study at a single center

Yuya Nagai, Yuma Yasuda, Kai Osawa et al. Nov 03, 2025 pp. 1930-1930 10.1182/blood-2025-1930

Abstract Background CD19-directed chimeric antigen receptor (CAR) T-cells have revolutionized the treatment of relapsed/refractory large B-c...

Prognostic value of immunoparesis, lymphopenia, high serum ferritin, and suppression of the non-involved serum free light chains (niFLC) in relapsed and refractory multiple myeloma patients (RRMM) receiving bispecific antibodies

Valentina Cardenas Castro, Kevin Shim, Mariano Arribas et al. Nov 03, 2025 pp. 5772-5772 10.1182/blood-2025-5772

Abstract Background The advent of T-cell redirecting bispecific antibodies (BsAb) therapies has led to deeper and durable responses in patie...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page